Practical aspects in the diagnosis and management of aplastic anemia

Research output: Contribution to journalReview article

12 Scopus citations

Abstract

Aplastic anemia may result from several pathogenic mechanisms, the most common is idiopathic. The current definitive treatments for aplastic anemia are bone marrow transplantation (BMT) or immunosuppressive (IS) therapy. The benefits of each are comparable. However, certain subsets of patients derive superior benefit from one of the other. Bone marrow transplantation is the initial treatment of choice for young patients (<20 years old). It results in the complete reconstitution of hematopoiesis, whereas autologous hematopoietic remissions after IS therapy are more susceptible to relapse. Survival rates after BMT, in patients between the ages of 20 and 40, are comparable to those reported for IS therapy. Better survival rates after BMT have been achieved with improved conditioning regimens and graft-versus-host disease prophylaxis. For patients older than 40, the treatment of choice is IS. Long-term complications of IS therapy include recurrence and development of clonal myeloid disorders. Long-term complications after BMT include graft- versus host disease and secondary neoplasms. The IS regimen includes the combination of antithymocyte globulin and cyclosporin A. The addition of growth factor to the IS regimen seems promising; however, their use on their own is not recommended. Androgens have been shown to be inferior in the treatment of aplastic anemia. The role of BMT from an unrelated donor is being investigated.

Original languageEnglish (US)
Pages (from-to)159-169
Number of pages11
JournalAmerican Journal of the Medical Sciences
Volume313
Issue number3
DOIs
StatePublished - Jan 1 1997

Keywords

  • Bone marrow transplantation
  • Diagnosis
  • Immunosuppressive therapy
  • Outcome
  • Survival rate

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Practical aspects in the diagnosis and management of aplastic anemia'. Together they form a unique fingerprint.

Cite this